Investment Opportunity

Share Placement - Minomic International Ltd (Minomic)
Raising up to USD$14million (A$20 million) for 25.5% Equity Shareholding

The Company is funding to (a) retire the Australian Govt substantial equity position in the company at market competitive pricing (it has been in place for 10 years), and (b) to raise further working funds to pursue the commercialisation of MiCheck ® in key markets (China/USA) and will allow finalisation of manufacturing as well as rollout of the test via centralised laboratories.

Minomic is an immuno-oncology company founded in Sydney in 2007, which has developed a definitive diagnostic blood test for the early detection of prostate cancer - the MiCheck ® test. Clinical Studies have demonstrated significant improved performance over existing prostate cancer testing with a **95% Sensitivity Result**.

The MiCheck® test will result in a more reliable early detection of prostate cancer with;

- Significant healthcare cost savings
- Less patient anxiety and discomfort
- Reduced risk of infection from prostate biopsies

The Problem

- Prostate Cancer is the most common cancer in men
- Diagnosis of prostate cancer has been poorly addressed by available technologies such as the PSA test, resulting in misdiagnosis, overtreatment and generally poor health outcomes for men
- Men are, more than ever, unlikely to seek medical help due to this poor track record
- Men simply want to know the answer to the question: "Do I have prostate cancer?"

The Answer – The MiCheck® Test

- **MiCheck is a Simple Blood Test** - that detects a protein that is only present on cancer cells
- **MiCheck is 95% accurate** – far higher than standard PSA test – **reduces unnecessary biopsies**
- **MiCheck provides a YES/NO to cancer** and if **Yes – critically whether it is aggressive or non-aggressive**.

Compelling Advantages

The MiCheck® technology offers the ability to address a large unmet need in prostate cancer diagnosis and patient monitoring a USD$3 billion testing market.

The Opportunity

- A prostate diagnostic test with high specificity
- Provide a significant reduction in healthcare expenditures
- Improving quality of outcomes for patients and medical professionals
- Initial rollout of MiCheck® in the USA will be via the Laboratory Developed Test (LDT) pathway. This approach enables CLIA certified "High Complexity Laboratories" to internally validate MiCheck® in their own laboratory and make the test available to their referring clinicians. Minomic have signed a distribution/royalty agreement with Cirrus DX to distribute through their labs. The company is seeking broader independent FDA accreditation to supplement the Cirrus Dx agreement from the funds being raised. USA reimbursement is in place which will minimise the out of pocket expenses of patients.

The Current Medical Options

(A) Prostate Biopsy Surgery = Expensive, Painful, Complex & Time Consuming; OR
(B) MiCheck® Blood Test = Inexpensive, Painless, Simple & Immediate

Investment Exit

Minomic is working to create a liquidity event for investors via a trade sale, or alternatively a public listing, within a two to three-year time horizon. Presently, the company is engaged in discussions with three major diagnostic companies and three mid-tier urological cancer diagnostic companies under NDA for anticipated license agreement which could occur in 2019. This execution of a licence agreement will see a weighty return of capital and capital gain flowing to shareholders. The final exit with be a trade sale within three-years